Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyRec: Chemoradiation and Hyperthermia in Rectal Cancer
NCT01716949Phase 2Unknown
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Sep 2012
- Primary completion
- Jun 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, capecitabine, oxaliplatin in rectal cancer, sponsored by FAU Erlangen-Nürnberg Medical Faculty. Status: unknown.
02
Drugs
fluorouracilcapecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01716949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01716949.